We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Wegovy improved functional class vs. placebo at 1 year ...
In patients with hypertrophic cardiomyopathy (HCM), the first-in-class cardiac myosin inhibitor mavacamten (MyoKardia), on top of medical therapy, significantly improved hemodynamics, functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback